|
 |
CetrorelixThis page contains recent news articles, when available, and an overview of Cetrorelix but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Cetrorelix (when available) Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels. Cetrorelix competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. For the inhibition of premature LH surges in women undergoing controlled ovarian stimulation. Mechanism Of Action: Cetrorelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. It competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. News Articles on Cetrorelix AEterna Zentaris sells Quebec City building for US$7.1 million - Jun 27, 2008 The endocrinology and oncology drug developer said it will use the funds for its ongoing Phase 3 study of cetrorelix to treat enlarged prostate glands. New Brunswick Business Journal, Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six ... - Jun 27, 2008 The funds will be dedicated to our ongoing Phase 3 program with cetrorelix in benign prostatic hyperplasia." VIA Pharmaceuticals, Inc. (NASDAQ: VIAP), Financial News USA (press release), Wednesday's Biotechnology industry movers: (OTCBB: PTEO), (Nasdaq ... - Jun 19, 2008 Aeterna had their moments in mid May, when the company announced they began dosing in the safety study of its Phase 3 program with cetrorelix, HotStocked, AEterna Zentaris: Article on Phase 2 Trial with Cetrorelix in BPH ... - May 13, 2008 These results are part of previously disclosed Phase 2 data on cetrorelix in BPH through prior abstracts and poster presentations. The article is available FOXBusiness AEterna Zentaris Begins Dosing In Phase 3 Program With Cetrorelix ... - May 14, 2008 TO) announced that it has commenced dosing in the safety study of Phase 3 program with cetrorelix in benign prostatic hyperplasia. This 500-patient safety RTT News, AEterna Zentaris Says Article on Phase 2 Trial with Cetrorelix in ... - May 13, 2008 According to the company, the article refers to results of a Phase 2 trial with cetrorelix in BPH, which showed a prolonged improvement in BPH symptoms and RTT News, UPDATE 1-AEterna Zentaris doubles first-quarter loss - May 7, 2008 ...up from $7.9 million for the same time last year as it ramped up development of its lead product cetrorelix which is in Phase 3 trials. Reuters India, AEterna Zentaris Reports First Quarter 2008 Financial and ... - May 7, 2008 ...<< First Quarter 2008 Highlights - Cetrorelix: first patients treated in second efficacy trial of the Phase 3 program in benign prostatic hyperplasia (BPH); Canada NewsWire (press release), AEterna Zentaris to Present at Upcoming Rodman & Renshaw Global ... - May 15, 2008 Titled, "Luteinizing Hormone-Releasing Hormone (LHRH) Receptors in BPH as Potential Molecular Targets for Therapy with Cetrorelix", the presentation will Earthtimes (press release), AEterna loss grows to $10.9-million - May 7, 2008 The $5.8-million R&D increase was "mainly related to the advancement of our lead product cetrorelix in Phase 3." The $10.9-million loss amounted to 20 cents ReportonBusiness.com, AEterna Zentaris Announces First Patient Dosing For Safety Trial - May 15, 2008 This 500-patient safety trial is the third of three Phase 3 studies - planned to enroll a total of 1500 patients - to define the role of cetrorelix in the Pharmaceutical Online (press release), AEZS: Ph II Data re BPH to be Published in European Urology Journal - May 13, 2008 The article refers to results of a Phase 2 trial with cetrorelix in BPH, which showed a prolonged improvement in BPH symptoms and uroflow, persisting up to Trading Markets (press release), Market Report -- In Play (WIRES) - May 14, 2008 AEterna Zentaris (AEZS) reported dosing has commenced in the safety study of the co's Phase 3 program with cetrorelix in benign prostatic hyperplasia. MSN Money AEterna Zentaris' Partner, Spectrum, Provides Update on Ozarelix ... - 23 Apr 2008 ..."AEterna Zentaris remains committed about the potential of LHRH antagonists for BPH, particularly for our lead candidate cetrorelix, which has produced Canada NewsWire (press release), Calamos Asset Management Q1 Profit Plunges - Quick Facts [CLMS] - 23 Apr 2008 Paul Blake, Senior Vice President and Chief Medical Officer of AEterna Zentaris, said in a statement that its lead candidate cetrorelix is currently being RTT News, Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for ... - Mar 26, 2008 ..."We are very pleased to be on track with our Phase 3 clinical program for cetrorelix in BPH," said David J. Mazzo, Ph.D., President and CEO, PR Newswire (press release), Aeterna Zentaris Begins Second Phase 3 Trial Of Cetrorelix For ... - Mar 26, 2008 TO) announced that it has commenced dosing with its flagship product candidate, cetrorelix in the second efficacy study of its Phase 3 program in benign RTT News, AEterna CEO quits amid boardroom battle - Apr 12, 2008 ...was to build a specialty company focusing on men's urology, that would market Cetrorelix, AEterna's treatment for enlarged prostate glands, on its own. The Gazette (Montreal), Chuck Lieberman Of Advisors Capital Management: I Don't Think ... - Mar 26, 2008 TO), a biopharmaceutical company, announced the initiation of Phase 3 trial in the second efficacy study of cetrorelix for benign prostatic hyperplasia or RTT News, Scientists test new prostate disease drug - Mar 27, 2008 Aeterna Zentaris Inc. said the double-blind study to be conducted in Europe will test the clinical effectiveness of cetrorelix, a luteinizing United Press International Latest in business - Mar 26, 2008 Aeterna Xentaris said today it began its second phase 3 trial for its drug cetrorelix, used to treat benign prostatic hyperplasia, a non-cancerous Canada.com, PDI Signs 4-year Deal To Promote Novartis Product In US - Apr 11, 2008 ...on our Phase 3 program with cetrorelix in benign prostatic hyperplasia or BPH and our Phase 2 program with AEZS-108 for endometrial and ovarian cancer. RTT News, Market Report -- In Play (WIRES) - Mar 26, 2008 Aeterna Zentaris (AEZS) announces dosing has commenced with its flagship product candidate, cetrorelix, in the second efficacy study of its Phase 3 program MSN Money Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 ... - Mar 5, 2008 Year marked by strengthened leadership team and the initiation of Phase 3 program for cetrorelix in BPH All amounts are in US dollars QUEBEC CITY, PR Newswire (press release), UPDATE 1-AEterna drops to a fourth-quarter loss - Mar 5, 2008 ...almost double the $7.9 million for the same quarter in 2006 due to the Phase 3 development of cetrorelix, its treatment for enlarged prostrate glands. Reuters AEterna Zentaris "buy," target price reduced - Mar 6, 2008 The company’s clinical programme for Cetrorelix is proceeding at a slow pace and a similar delay is expected in Ozarelix’s clinical development, newratings.com, Suit opposes Medicare denials of off-label - Jan 14, 2008 So for the past eight years, her doctor has had her on daily doses of Cetrotide (cetrorelix acetate), a drug that is normally used to prevent premature Checkbiotech.org (press release), UPDATE 1-aeterna loss grows on R&D expenses - Nov 7, 2007 ...million a year earlier, due to additional expenses from its Phase 3 cetrorelix cancer treatment program and earlier clinical-stage development programs. Reuters aeterna Zentaris Reports Third Quarter 2007 Financial and ... - Nov 7, 2007 The increase in consolidated R&D expense is related to the additional expenses incurred for the ongoing Phase 3 program with cetrorelix in BPH, CNNMoney.com AEterna Zentaris Announces Outcome of Management's Strategic Review - Oct 2, 2007 AEterna Zentaris has prioritized its pipeline, developed a partnering strategy and determined the value of its most immediate assets: Cetrorelix Cetrorelix, CNNMoney.com UPDATE 1-Aeterna seeks partner for BPH treatment - Oct 2, 2007 TO: Quote, Profile, Research) unveiled a new strategic plan on Tuesday that includes commercialization of its key Cetrorelix drug and the sale of some Reuters UPDATE 2-Aeterna seeks partner for BPH treatment - Oct 2, 2007 It said it will seek a commercialization partner for Cetrorelix, its treatment for benign prostatic hyperplasia (BPH), the increase in the size of the Reuters AEterna downgraded as delay seen for key treatment - Oct 3, 2007 The company said during a conference call on Tuesday that it expects to launch Cetrorelix, which is currently in Phase 3 trials, as a BPH treatment by Reuters AEterna Zentaris Announces Outcome of Management's Strategic Review - Oct 3, 2007 After defining the critical path to registration, the Company expects to launch cetrorelix in the BPH indication in 2011. future. PharmaLive.com (press release), Reuters Canada Business Summary - Oct 2, 2007 The company said it will seek a commercialization partner for Cetrorelix, a treatment for benign prostatic hyperplasia (BPH). NEW YORK (Reuters) - Union ReportonBusiness.com, AEterna Zentaris Reveals Outcome Of Review Of Pipeline And ... - Oct 2, 2007 AEterna Zentaris said it would eventually seek a commercialization partner as cetrorelix has the potential for base case peak annual sales of about $200 Trading Markets, AEterna Zentaris Reports Second Quarter 2007 Financial and ... - Aug 14, 2007 Most importantly, we commenced patient dosing for the first trial of the Phase 3 program for cetrorelix in BPH. With recruitment underway, our other CNNMoney.com AEterna Zentaris Q2 loss deepens to US$4.8M; founder leaves board - Aug 14, 2007 Clinical trials are proceeding on several promising treatments, including its flagship cetrorelix, along with ozarelix and perifosine. The Canadian Press, AEterna Zentaris completes management team with the appointment of ... - Aug 16, 2007 ..."The appointment of Dr. Blake is timely and critical as our foremost priority is to bring our flagship product candidate, cetrorelix, to market as a novel CNNMoney.com AEterna Zentaris mulls partnership - Aug 15, 2007 ...endocrine drug developer AEterna Zentaris Inc. is in preliminary discussions with potential partners about developing its flagship Cetrorelix compound. London Free Press, AEterna Zentaris Q2 loss deepens to US$4.8M; founder leaves the board - Aug 14, 2007 ..."Most importantly, we commenced patient dosing for the first trial of the Phase 3 program for cetrorelix in BPH (benign prostatic hyperplasia)," he stated. Canada East, The lost summer of Phil - Aug 14, 2007 AEterna regained the exclusive worldwide rights (aside from Japan) for Cetrorelix from Solvay Pharmaceuticals in all indications, including endometriosis, Sportsnet.ca, Fake menopause can cheat cancer - Jul 8, 2007 Online - International News Network,Dr Kate Stern and colleagues at the Royal Women’s Hospital in Melbourne said the treatment, cetrorelix, could offer these women another option. Tx helps CA patients have babies - Jul 27, 2007 National Review of Medicine,The patients were given three injections of cetrorelix, a GnRH antagonist, at four day intervals to coincide with their chemo treatments. Promising New Research Offers Hope To Female Cancer Patients At ... - Jul 10, 2007 Medical News Today (press release),The women were given the GnRH antagonist cetrorelix by 3 subcutaneous injections, each of them four days apart, concurrently with their chemotherapy. Merck Serono's Fertility Treatment Pergoveris Approved in European ... - Jun 29, 2007 PharmaLive.com (press release),Cetrotide(r) (cetrorelix acetate) to prevent a premature ovulation; Ovitrelle(r) (choriogonadotropin alfa), to help follicles mature and release eggs; A New Era at AEterna - 25 May 2007 Motley FoolLead hormone therapy products cetrorelix and ozarelix aim to compete with Lupron Depot (a product of TAP Pharma, the joint venture of Abbott Labs and AEterna Zentaris Reports First Quarter 2007 Financial and ... - May 2, 2007 CNW Telbec (Communiqués de presse),Positive Phase 2a results in Japan with cetrorelix in BPH - The Company, along with its Japanese partner, Shionogi, announced positive results for a Phase AEterna Zentaris Bolsters Management Team with Two Key Positions Named - May 7, 2007 CNW Telbec (Communiqués de presse),..."Nick's strong regulatory and drug development expertise is essential as we advance our Phase 3 program for cetrorelix in BPH, preparing for the expected AEterna Zentaris Reports First Patients Treated with Cetrorelix ... - Apr 19, 2007 CNW Telbec (Communiqués de presse),As previously announced, the first study of the Phase 3 program titled, "Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic AEterna Zentaris Reports Positive Results with Cetrorelix in BPH ... - Mar 29, 2007 Drug Newswire (press release),Results showed that cetrorelix, the Company's lead luteinizing hormone-releasing hormone (LHRH) antagonist, was safe and well tolerated at all dosage Æterna Zentaris Initiates First Study of Phase 3 Program with ... - Jan 9, 2007 PipelineReview.com (press release),The first study of the previously announced Phase 3 program titled, "Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a Aeterna Zentaris begins studies - Jan 9, 2007 Montreal Gazette (subscription),Aeterna Zentaris Inc. begins the first of three studies in Phase 3 trial for cetrorelix compound, used in treatment of abnormal benign growth of prostate. AEterna starts Phase 3 study of prostate treatment - Jan 8, 2007 Reuters Canada,TORONTO (Reuters) - AEterna Zentaris said on Monday it began the first of three studies in its Phase 3 program of cetrorelix, its flagship treatment for AEterna starts Phase 3 study of prostate treatment - Jan 8, 2007 Reuters Canada,TO: Quote) said on Monday it began the first of three studies in its Phase 3 program of cetrorelix, its flagship treatment for abnormal benign growth of Pharma Sector : Few Newsmakers Of The Week - MedImmune, Shire Plc ... - Jan 13, 2007 Trading Markets,The company also initiated the first of three studies in its Phase 3 program with cetrorelix for patients with benign or noncancerous enlargement of the Jump in oil prices helps send Toronto stocks higher, NY lower - Jan 8, 2007 Canada.com,...-Aeterna Zentaris Inc. (TSX:AEZ) shares rose eight cents to $4.60 after it began the first of three studies in a Phase 3 trial for its cetrorelix compound, Gains on TSX deteriorate - Jan 8, 2007 Montreal Gazette,Aeterna Zentaris Inc. (TSX:AEZ) shares were unchanged at $4.52 after the firm began the first of three studies in a Phase 3 trial for its cetrorelix Morning business file: Diamond find (9 am) - Jan 8, 2007 Edmonton Journal (subscription),Aeterna Zentaris Inc. (TSX:AEZ) shares rose five cents to $4.57 after the firm began the first of three studies in a Phase 3 trial for its cetrorelix (PRN) - SnoCountry Reports Latest Skiing Conditions Information ... - Jan 8, 2007 Bolsamania.com,...(PRN) - AEterna Zentaris Initiates First Study of Phase 3 Program with Cetrorelix in BPH - 600 Patient Trial Conducted in the United States and Canada . Æterna Zentaris to Initiate Phase 3 Program with Cetrorelix in BPH ... - Nov 30, 2006 PipelineReview.com (press release),Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1 year placebo-controlled efficacy study and long-term safety AEterna Zentaris to Initiate Phase 3 Program with Cetrorelix in BPH - Nov 29, 2006 CNW Telbec (Communiqués de presse),The first study of this Phase 3 program titled, "Cetrorelix pamoate intermittent IM dosage regimens in patients with symptomatic BPH: a 1 year UPDATE 1-AEterna to start cetrorelix Phase 3 by year-end - Nov 29, 2006 ReutersTO: Quote, Profile, Research) said on Wednesday it plans to initiate before year-end a Phase 3 trial for cetrorelix, a luteinizing hormone-releasing hormone Market Report -- In Play (AEZS) - Nov 29, 2006 MSN MoneyAEterna Zentaris to initiate Phase 3 program with Cetrorelix in BPH Co announces its plan to initiate its Phase 3 program in benign prostatic hyperplasia AEterna Zentaris (AEZS) to Initiate Phase 3 Program in Benign ... - Nov 29, 2006 StreetInsider.com (subscription),Patients will then be allocated to cetrorelix in a double-blind, randomized, double-dummy, placebo-controlled fashion. The primary efficacy endpoint of this AEterna Zentaris to Webcast Analyst Meeting in Toronto on November ... - Nov 27, 2006 PharmaLive.com (press release),Company management and opinion leaders will present and discuss the development of its lead compounds cetrorelix, ozarelix and perifosine, as well as other Pharma Sector: Few Newsmakers Of The Week - Teva, Barr, Genta ... - Dec 1, 2006 Trading Markets,With the FDA accepting its initial new drug application of cetrorelix, AEterna Zentaris may well be on its way to penetrate a $4 billion plus market such as Toronto stocks seen up with Bombardier, M&A fever - Nov 29, 2006 Reuters Canada,TO: Quote) will be in the spotlight after saying it plans to initiate a Phase 3 trial for cetrorelix before year-end. On the commodities front, Toronto stocks seen up with Bombardier, M&A fever - Nov 29, 2006 ReutersTO: Quote, Profile, Research) will be in the spotlight after saying it plans to initiate a Phase 3 trial for cetrorelix before year-end. (PRN) - Seagate Savvio Small Form Factor Enterprise Hard Drives ... - Nov 29, 2006 Bolsamania.com,...(PRN) - AEterna Zentaris to Initiate Phase 3 Program with Cetrorelix in BPH ... [+]. (PRN) - Archemix Grants Ribomic a License to its Intellectual Property Brand Names/Synonyms: Cetrorelix is also known by the following brand names and/or synonymsCetrorelix; Cetrorelix Acetate; Cetrorelix [Inn]; Cetrorelixum [Inn-Latin]; Cetrotide; Cetyl Pyridinium Bromide; Cetyl Pyridinium Chloride; Cetyl Pyridinium Chloride for Synthesis; Cetylpyridinium Chloride Monohydrate; Chondroitin Hydrochloride; Hexadecyl Pyridinium Bromide; Hexadecylpyridinium Chloride Monohydrate; N-Cetylpyridinium Bromide; N-Hexadecylpyridinium Bromide; Pyrisept; SB-75 Drug Category: Cetrorelix is categorized under the following by the FDA: Infertility Agents; Hormone Antagonists; ATC:H01CC02 Dosage Forms: POWDER FOR SOLUTION Absorption: Rapidly absorbed following subcutaneous injection. The mean absolute bioavailability following subcutaneous administration to healthy female subjects is 85%. Interactions: -->Interactions for Cetrorelix: No formal drug interaction studies have been performed with Cetrotide®. Chemical IUPAC Name: Not Available : |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines mongabay.com
COPYRIGHT 2007 MONGABAY.COM |